|
|
 |
|
Viewing report
|
|
|
|
Multi Client Study: Opportunities Assessment for the Hepatitis C Therapeutics Market in Indonesia
Frost & Sullivan, Dec 2009, Pages: 58
This Frost & Sullivan research service titled Multi Client Study: Opportunities Assessment for the Hepatitis C Therapeutics Market in Indonesia provides an overview of the market, government initiatives, patient load and classification, patient forecasts, treatment regimens, product launches, and challenges faced by physicians.
Market Overview
Small Molecule Anti-virals with Optimized Efficacy and Fewer Side Effects Drive Growth in the Hepatitis C Therapeutics Market in Indonesia
Regular blood screening conducted in hospitals for at-risk patients, particularly injecting drug users (IDUs), has expanded the patient base and enhanced prospects for the hepatitis C therapeutics market in Indonesia. Moreover, increasing health awareness in Indonesia has encouraged the population (mostly urban) to opt for annual physical examinations and regular blood screening that enable the detection of hepatitis C. Small molecule anti-virals with improved efficacy are poised to take the market forward. Several strategies are being explored in clinical trials, including add-on therapy to the current standard of care, interferon replacement, and ribavirin replacement. Refined versions of interferons, oral formulations of small molecule inhibitors, and the new drug class known as protease inhibitors are in the pipeline and represent the future of hepatitis C virus (HCV) treatment.
Despite the initiatives undertaken, only 2 percent of those diagnosed are placed under treatment, primarily because of the lack of government reimbursement. Treatment of hepatitis C is restrained by the high cost of medication for patients who do not have health insurance. 'While Indonesia offers healthcare coverage to its population, many of the poor people are unable to apply for the insurance,' says the analyst. 'Those not entitled are expected to bear the cost themselves, which is approximately $1,000 per month.' The low rate of treatment and compliance is also caused by patients’ fear of side effects associated with treatment. These include bone marrow depression, flu-like symptoms, neuropsychiatric disorders, and autoimmune syndromes. Besides limited efficacy for those infected with genotype-1 strain, an inconvenient mode of administration has also contributed to non-compliance.
Studies have shown that patients treated with combination therapy of the two drugs are more likely to reach sustained virological response than those treated with monotherapy. With this, more patients are likely to accept treatment, as there is a better chance for them to completely recover from hepatitis C. In Indonesia, the standard treatment for HCV is Peg intron; Peg intron + Ribavirin; Pegasys; and Pegasys + Ribavirin. Physicians interviewed agreed that patients respond better to combination therapy and recovery rates are higher for patients on Pegylated interferon (Peg intron or Pegasys) + Ribavirin. Additionally, most patients are HIV positive, making treatment more difficult, as the possibility of co-infection is higher among these patients.
Companies that offer treatments with improved efficacy and fewer side effects, combined with disease education, can help overcome the challenges clouding the market landscape. Encouraging better compliance at present will enhance the likelihood of future compliance, especially for improved treatments. Creating incentives for patients to stay on HCV treatment will improve the chances of patient compliance. In order to increase their HCV market share with newer drugs, companies must make sure that patients are aware of their disease status. 'Awareness programs are mostly centered in urban areas, with the aid of media such as television and internet as a source of information delivery,' says the analyst. 'Outreach programs must target rural areas to stop the onslaught of the disease.' Creating marketing campaigns that highlight better efficacy, partnerships with governments to lower costs but increase distribution, and broadening diagnosis efforts will increase market presence.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Hepatitis C Therapeutics Market—Thailand
Hepatitis C Therapeutics Market – Taiwan
Multi Client Study: Opportunities Assessment for the Hepatitis C Therapeutics Market in Australia
R&D Trends: Hepatitis C
Hepatitis C Viral Infection - After Protease Inhibitors What Is Next?
Competitor Analysis: Targeted Therapy of Hepatitis C
Hepatitis Therapeutics Market to 2016 - Strong Hepatitis-C Pipeline and Cost Effective Treatments will Drive the Global Hepatitis Market
Hepatitis C Virus - Protease Inhibitors Bring Change in the Treatment Paradigm for Hepatitis C Virus Infection - What Next?
Global Hepatitis C Virus (HCV) Market– An Analysis
Clinical Dilemmas in Viral Liver Disease
|
|
|
|
